JPH07330501A - 肝保存剤および肝保存方法 - Google Patents
肝保存剤および肝保存方法Info
- Publication number
- JPH07330501A JPH07330501A JP6131654A JP13165494A JPH07330501A JP H07330501 A JPH07330501 A JP H07330501A JP 6131654 A JP6131654 A JP 6131654A JP 13165494 A JP13165494 A JP 13165494A JP H07330501 A JPH07330501 A JP H07330501A
- Authority
- JP
- Japan
- Prior art keywords
- liver
- solution
- preservative
- perfusion
- preserving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 81
- 239000003755 preservative agent Substances 0.000 title claims abstract description 37
- 230000002335 preservative effect Effects 0.000 title claims description 33
- 238000000034 method Methods 0.000 title claims description 28
- 238000004321 preservation Methods 0.000 title description 19
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 230000010412 perfusion Effects 0.000 claims abstract description 13
- -1 phosphoric acid diester compound Chemical class 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 4
- 230000003204 osmotic effect Effects 0.000 claims abstract description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 30
- 239000003761 preservation solution Substances 0.000 claims description 18
- 230000002440 hepatic effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000010410 reperfusion Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 238000012752 Hepatectomy Methods 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 10
- 230000004089 microcirculation Effects 0.000 abstract description 6
- 238000002054 transplantation Methods 0.000 abstract description 6
- 229960005070 ascorbic acid Drugs 0.000 abstract description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 5
- 230000034994 death Effects 0.000 abstract description 4
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 3
- 239000011668 ascorbic acid Substances 0.000 abstract description 3
- 229930003799 tocopherol Natural products 0.000 abstract description 3
- 235000010384 tocopherol Nutrition 0.000 abstract description 3
- 239000011732 tocopherol Substances 0.000 abstract description 3
- 229960001295 tocopherol Drugs 0.000 abstract description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract description 3
- 210000005229 liver cell Anatomy 0.000 abstract 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- VIHIKSJKXIMMLV-FZTHFCCHSA-M potassium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] phosphate Chemical compound [K+].C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OP([O-])(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O VIHIKSJKXIMMLV-FZTHFCCHSA-M 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000000162 organ preservation solution Substances 0.000 description 3
- 210000003240 portal vein Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000017657 Menopausal disease Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124428 anticataract agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002683 reaction inhibitor Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6131654A JPH07330501A (ja) | 1994-06-14 | 1994-06-14 | 肝保存剤および肝保存方法 |
| US08/489,676 US5660976A (en) | 1994-06-14 | 1995-06-13 | Method for preserving a liver by perfusion with or storage in a solution containing ascorbyl tocopheryl phosphodiester |
| ES95109088T ES2137408T3 (es) | 1994-06-14 | 1995-06-13 | Composicion conservante de injerto hepatico, y metodo para la conservacion viable del injerto hepatico. |
| DE69512834T DE69512834T2 (de) | 1994-06-14 | 1995-06-13 | Lebertransplantat-Konservierungsmittelmischung und ein Verfahren zur Lebendkonservierung des Lebertransplantats |
| AT95109088T ATE185676T1 (de) | 1994-06-14 | 1995-06-13 | Lebertransplantat-konservierungsmittelmischung und ein verfahren zur lebendkonservierung des lebertransplantats |
| EP95109088A EP0687411B1 (en) | 1994-06-14 | 1995-06-13 | Hepatic graft preservative composition and a method for viable preservation of the hepatic graft |
| KR1019950015777A KR960000021A (ko) | 1994-06-14 | 1995-06-14 | 간보존제 및 간 보존방법 |
| TW084106148A TW278024B (enExample) | 1994-06-14 | 1995-06-14 | |
| CA002151750A CA2151750A1 (en) | 1994-06-14 | 1995-06-14 | Hepatic graft preservative composition and a method for viable preservation of the hepatic graft |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6131654A JPH07330501A (ja) | 1994-06-14 | 1994-06-14 | 肝保存剤および肝保存方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07330501A true JPH07330501A (ja) | 1995-12-19 |
Family
ID=15063111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6131654A Pending JPH07330501A (ja) | 1994-06-14 | 1994-06-14 | 肝保存剤および肝保存方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5660976A (enExample) |
| EP (1) | EP0687411B1 (enExample) |
| JP (1) | JPH07330501A (enExample) |
| KR (1) | KR960000021A (enExample) |
| AT (1) | ATE185676T1 (enExample) |
| CA (1) | CA2151750A1 (enExample) |
| DE (1) | DE69512834T2 (enExample) |
| ES (1) | ES2137408T3 (enExample) |
| TW (1) | TW278024B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006093314A1 (ja) * | 2005-03-04 | 2006-09-08 | National University Corporation, Tokyo Medical And Dental University | 臓器機能維持改善液 |
| JP2007507690A (ja) * | 2003-09-29 | 2007-03-29 | 株式会社 オキシジェニクス | 臓器機能の評価方法 |
| WO2021014997A1 (ja) * | 2019-07-23 | 2021-01-28 | 株式会社Ｓｃｒｅｅｎホールディングス | 灌流液および灌流方法 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162450A (en) * | 1995-05-15 | 2000-12-19 | Avon Products, Inc. | Uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same |
| US5922335A (en) * | 1995-05-15 | 1999-07-13 | Avon Products, Inc. | Uses for ascorbyl-phosphoryl-cholesterol in topical compositions |
| KR100516480B1 (ko) * | 2003-05-16 | 2005-09-23 | 한국과학기술연구원 | 저온 플라즈마를 이용한 촉매 환원 방법 |
| US7448392B2 (en) * | 2003-12-22 | 2008-11-11 | Philip Morris Usa Inc. | Smoking articles and filters with carbon-coated molecular sieve sorbent |
| US20080161423A1 (en) * | 2005-03-04 | 2008-07-03 | Atsushi Kudo | Organ Function Maintaining or Amelorating Solution |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3460065D1 (en) * | 1983-03-11 | 1986-05-07 | Firmenich & Cie | Process for the preparation of an isomeric composition of 1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol, use of the obtained composition and intermediate carbinols |
| JPS59219295A (ja) * | 1983-05-30 | 1984-12-10 | Senjiyu Seiyaku Kk | リン酸ジエステルまたはその塩およびそれらの製造法 |
| JPS62205091A (ja) | 1986-03-04 | 1987-09-09 | Senjiyu Seiyaku Kk | 新規なリン酸ジエステルならびにその塩、その製造法およびそれを含有する製剤 |
| JPH0781138B2 (ja) * | 1986-12-02 | 1995-08-30 | 株式会社資生堂 | 抗酸化剤 |
| JP2526059B2 (ja) | 1987-04-28 | 1996-08-21 | 千寿製薬株式会社 | 抗潰瘍剤 |
| JPS6427044A (en) | 1987-07-23 | 1989-01-30 | Sony Corp | Optical pickup |
| PH25859A (en) * | 1988-01-11 | 1991-12-02 | Takeda Chemical Industries Ltd | Composition for treatment of ischemic disorder |
| JP2714678B2 (ja) | 1988-01-11 | 1998-02-16 | 千寿製薬株式会社 | 虚血性臓器障害予防・治療剤 |
| US4939128A (en) * | 1988-04-25 | 1990-07-03 | Takeda Chemical Industries, Ltd. | Ester of ascorbic acid 2-phosphate and pharmaceutical use |
| JPH0244478A (ja) | 1988-08-05 | 1990-02-14 | Nec Corp | 半導体記憶素子 |
| JP2854631B2 (ja) | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤 |
| US5145771A (en) * | 1990-04-12 | 1992-09-08 | The University Of North Carolina At Chapel Hill | Rinse solution for organs and tissues |
| CH683485A5 (fr) * | 1990-11-20 | 1994-03-31 | Pasteur Merieux Serums Vacc | Solutions de perfusion, de conservation et de reperfusion d'organes. |
| TW262386B (enExample) * | 1992-09-30 | 1995-11-11 | Senju Pharma Co |
-
1994
- 1994-06-14 JP JP6131654A patent/JPH07330501A/ja active Pending
-
1995
- 1995-06-13 US US08/489,676 patent/US5660976A/en not_active Expired - Fee Related
- 1995-06-13 AT AT95109088T patent/ATE185676T1/de active
- 1995-06-13 ES ES95109088T patent/ES2137408T3/es not_active Expired - Lifetime
- 1995-06-13 EP EP95109088A patent/EP0687411B1/en not_active Expired - Lifetime
- 1995-06-13 DE DE69512834T patent/DE69512834T2/de not_active Expired - Fee Related
- 1995-06-14 TW TW084106148A patent/TW278024B/zh active
- 1995-06-14 KR KR1019950015777A patent/KR960000021A/ko not_active Abandoned
- 1995-06-14 CA CA002151750A patent/CA2151750A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007507690A (ja) * | 2003-09-29 | 2007-03-29 | 株式会社 オキシジェニクス | 臓器機能の評価方法 |
| WO2006093314A1 (ja) * | 2005-03-04 | 2006-09-08 | National University Corporation, Tokyo Medical And Dental University | 臓器機能維持改善液 |
| WO2021014997A1 (ja) * | 2019-07-23 | 2021-01-28 | 株式会社Ｓｃｒｅｅｎホールディングス | 灌流液および灌流方法 |
| JP2021017423A (ja) * | 2019-07-23 | 2021-02-15 | 株式会社Ｓｃｒｅｅｎホールディングス | 灌流液および灌流方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0687411B1 (en) | 1999-10-20 |
| TW278024B (enExample) | 1996-06-11 |
| EP0687411A1 (en) | 1995-12-20 |
| US5660976A (en) | 1997-08-26 |
| CA2151750A1 (en) | 1995-12-15 |
| DE69512834T2 (de) | 2000-04-13 |
| KR960000021A (ko) | 1996-01-25 |
| ES2137408T3 (es) | 1999-12-16 |
| DE69512834D1 (de) | 1999-11-25 |
| ATE185676T1 (de) | 1999-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SUMIMOTO et al. | 24-hour rat liver preservation using UW solution and some simplified variants | |
| US5702881A (en) | Method and solution for organ preservation comprising retinal-derived growth factor, cyclodextrin, mucopolysaccharide and fluorocarbon | |
| US6569615B1 (en) | Composition and methods for tissue preservation | |
| US8288084B2 (en) | Composition and method for flushing and cold/cryo preserving organs, tissues, and cells | |
| Momii et al. | TIME-RELATED MORPHOLOGICAL CHANGES IN COLD-STORED RAT LIVERS: A COMPARISON EURO-COLLINS SOLUTION WITH UW SOLUTION | |
| JPH0768082B2 (ja) | 臓器保存用溶液 | |
| CA2112952A1 (en) | Methods, apparatus and perfusion-solutions for preservation of explanted organs | |
| US5075210A (en) | Preservation of the heart for transplantation | |
| CA1317225C (en) | Use of adenosine, hypoxanthine and ribose-containing solution for improved protection of the heart during surgery | |
| JP4603246B2 (ja) | 臓器保護溶液 | |
| Kevelaitis et al. | Coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: patterns and contributing factors | |
| Fahy | Analysis of “solution effects” injury: rabbit renal cortex frozen in the presence of dimethyl sulfoxide | |
| JPH07330501A (ja) | 肝保存剤および肝保存方法 | |
| US8512940B2 (en) | Method for preserving liver in a solution comprising dibutyryl cAMP | |
| Totsuka et al. | Attenuation of ischemic liver injury by prostaglandin E1 analogue, misoprostol, and prostaglandin I2 analogue, OP-41483 | |
| US7014990B2 (en) | Machine perfusion solution for organ and biological tissue preservation | |
| Mohara et al. | A comparative study of Celsior and University of Wisconsin solutions based on 12-hr preservation followed by transplantation in canine models | |
| Toledo-Pereyra et al. | Small bowel preservation: Comparison of perfusion and nonperfusion systems | |
| JP2000515115A (ja) | ウイルス感染及び細菌感染症治療用および臓器冷凍保存用組成物 | |
| Fuckert et al. | A ROLE FOR SODIUM IN HYPOXIC BUT NOT IN HYPOTHERMIC INJURY TO HEPATOCYTES AND LLC-PK 1 CELLS1 | |
| EP0664953B1 (en) | Lung graft preservative composition and a method for viable preservation of lung grafts | |
| US20160088832A1 (en) | Formulations containing poly (0-2 hydroxyethyl) starch for increasing the oxygen-content, stability and shelf life of an organ and tissue preservation solution | |
| Mohara et al. | The effect of Celsior solution on 12-hour cardiac preservation in comparison with University of Wisconsin solution | |
| D'Alessandro et al. | Effect of drug treatment on liver-slice function following 72-hour hypothermic perfusion | |
| Takeuchi et al. | Prolonged preservation of the blood-perfused canine heart with glycolysis-promoting solution |